We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 2.98 | 1.85% | 163.79 | 164.25 | 160.74 | 161.85 | 5,850,104 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Friday said it filed a supplemental new-drug application with the U.S. Food and Drug Administration for the expanded use of the cancer drug Imbruvica.
Janssen said it is seeking approval of Imbruvica in combination with rituximab for the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The company said the filing is based on positive results from a phase 3 study of the combination that met the primary endpoints of progression-free survival and overall survival compared to the chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab.
Imbruvica, which is jointly developed and commercialized by J&J's Janssen Biotech Inc. unit and AbbVie Inc.'s (ABBV) Pharmacyclics LLC, was first approved by the FDA in 2013 and is currently indicated in six disease areas.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 08, 2019 08:12 ET (13:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
